DocGo Inc.
For the period ended Aug 16, 2026. Filed Aug 17, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Aug 16, 2026 · Filed Aug 17, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Forward-Looking Statements
Forward-Looking Statements
This earnings release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the plans, strategies, outcomes, and prospects, both business and financial, of the Company, including the Company’s expectations around projected revenues and adjusted EBITDA for fiscal year 2026; the performance and growth of SteadyMD and the Company’s mobile phlebotomy business and other core business lines; completion of the acquisition of Hicuity Health and successful integration of the business; the performance and growth of Hicuity; the availability of debt financing from Perceptive Advisors following the acquisition of Hicuity; the launch of new Mobile Health programs; the demand for and expansion of the Company’s services; cash flow and cash collections; the Company’s cash balances; margin improvements; and the Company’s achievement of profitability. These statements are based on the beliefs and assumptions of the Company’s management. Although the Company believes that its plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, the Company cannot assure you that it will achieve or realize these plans, intentions, outcomes, results or expectations. Accordingly, you should not place undue reliance on such statements. All statements other than statements of historical fact are forward-looking, including, but not limited, to statements regarding the Company’s future actions, business strategies or models, plans, goals, future events, future revenues, future margins, current and future revenue guidance, future growth or performance, financing needs, business trends, results of operations, objectives and intentions with respect to future operations, services and products, and new and existing contracts or partnerships. In some cases, these statements may be preceded by, followed by or include the words “believes,” “estimates,” “expects,” “projects,” “forecasts,” “may,” “might,” “will,” “should,” “could,” “can,” “would,” “design,” “potential,” “seeks,” “plans,” “scheduled,” “anticipates,” “intends” or the negative of these terms or similar expressions.
Forward-looking statements are inherently subject to substantial risks, uncertainties and assumptions, many of which are beyond the Company’s control, and which may cause its actual results or outcomes, or the timing of its results or outcomes, to differ materially from those contained in its forward-looking statements, including, but not limited to the following: impacts related to the wind down of migrant-related services; the Company’s ability to continue as a going concern; the Company’s ability to maintain its listing on Nasdaq; the Company’s ability to pursue strategic initiatives to deliver on shareholder value; the Company’s ability to expand its programs with insurance partners, hospital systems, municipalities and other strategic partners; the Company’s ability to successfully implement its business strategy, including delivering value to shareholders via buybacks and funding new strategic relationships; the Company’s ability to establish, maintain and grow customer relationships; the Company’s ability to execute projects to the satisfaction of its customers; the Company’s ability to grow demand for its care gap closure programs and other services; the Company’s ability to maintain or grow its cash balances; the Company’s reliance on and ability to maintain its contractual relationships with its healthcare provider partners and other strategic partners; the Company’s ability to compete effectively in a highly competitive industry, including conditions in the healthcare transportation and mobile health services markets; the Company’s ability to maintain existing contracts; the Company’s reliance on government contracts, including changes in government spending on healthcare and other social services; the Company’s ability to effectively manage its growth; the Company’s financial performance and future prospects; the Company’s ability to deliver on its business strategies or models, plans and goals; the Company’s ability to expand geographically; the Company’s M&A activity and success of its acquisition strategy; the Company’s ability to retain its workforce and management personnel and successfully manage leadership transitions; the availability of healthcare professionals and other personnel; changes in the cost of labor; the Company’s ability to collect on customer receivables; risks associated with the Company’s share repurchase program; overall macroeconomic and geopolitical conditions, including the interest rate environment, the inflationary environment, the potential recessionary environment, regional conflict and tensions, financial institution instability and the ongoing or any future shutdown of the U.S. federal government; the ability of the Company’s suppliers to meet its needs; the Company’s ability to obtain or maintain operating licenses; potential changes in federal, state or local government policies or priorities; expected impacts of geopolitical instability; the Company’s competitive position and opportunities, including its ability to realize the benefits from its operating model; the Company’s ability to improve gross margins; the Company’s ability to implement and deliver on cost-containment measures and ongoing cost rationalization initiatives; legislative and regulatory actions; the impact of legal proceedings and compliance risk; volatility of our stock price; the impact on the Company’s business and reputation in the event of information technology system failures, network disruptions, cyber incidents or losses or unauthorized access to, or release of, confidential information; the Company’s ability to comply with laws and regulations regarding data privacy and protection and other risk factors included in the Company’s filings with the Securities and Exchange Commission (“SEC”).
Moreover, the Company operates in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for the Company to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this earnings release. The results, events, and circumstances reflected in the forward-looking statements may not be achieved or occur, and actual results or outcomes could differ materially from those described in the forward-looking statements.
The forward-looking statements made in this earnings release are based on events or circumstances as of the date on which the statements are made. The Company undertakes no obligation to update any forward-looking statements made in this earnings release to reflect events or circumstances after the date of this earnings release or to reflect new information or the occurrence of unanticipated events, except as and to the extent required by law. The Company’s forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments.
| DocGo Inc. and SubsidiariesUNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS | ||
|---|---|---|
| June 30, 2026 | December 31, 2025 | |
| Unaudited | Audited | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $ 25,233,369 | $ 51,018,657 |
| Accounts receivable, net of allowance for credit loss of $8,540,616 and $8,299,053 as of June 30, 2026 and December 31, 2025, respectively | 86,219,100 | 92,893,216 |
| Prepaid expenses | 4,403,326 | 4,790,215 |
| Other current assets | 3,942,361 | 3,697,371 |
| Total current assets | 119,798,156 | 152,399,459 |
| Property and equipment, net | 12,711,083 | 14,558,427 |
| Intangibles, net | 1,410,254 | — |
| Restricted cash and cash equivalents | 6,937,746 | 1,466,121 |
| Restricted investments (amortized cost of $15,952,661 and $15,737,694 as of June 30, 2026 and December 31, 2025, respectively) | 15,900,466 | 15,845,875 |
| Operating lease right-of-use assets | 9,259,686 | 11,520,781 |
| Finance lease right-of-use assets | 16,756,910 | 17,420,424 |
| Deferred tax assets | 561,903 | 538,864 |
| Other assets | 3,480,045 | 3,353,061 |
| Total assets | $ 186,816,249 | $ 217,103,012 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $ 14,020,960 | $ 11,110,867 |
| Accrued liabilities | 39,952,129 | 42,789,440 |
| Notes payable, current | 48,036 | 51,740 |
| Due to seller | 779,332 | 336,982 |
| Contingent consideration, current | 7,900,376 | 3,040,377 |
| Operating lease liability, current | 3,991,429 | 4,650,953 |
| Finance lease liability, current | 5,642,029 | 5,509,687 |
| Total current liabilities | 72,334,291 | 67,490,046 |
| Notes payable, non-current | 159,337 | 183,843 |
| Contingent consideration, non-current | 2,476,216 | 4,776,215 |
| Operating lease liability, non-current | 5,837,418 | 7,563,664 |
| Finance lease liability, non-current | 10,227,928 | 11,217,907 |
| Total liabilities | 91,035,190 | 91,231,675 |
| Commitments and contingencies (Note 19) | ||
| Stockholders’ equity: | ||
| Common stock ($0.0001 par value; 500,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 98,858,369 and 98,640,059 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively) | 9,886 | 9,864 |
| Additional paid-in-capital | 331,260,586 | 325,416,366 |
| Accumulated deficit | (214,385,203) | (183,801,795) |
| Accumulated other comprehensive income | 2,169,289 | 2,387,404 |
| Total stockholders’ equity attributable to DocGo Inc. and Subsidiaries | 119,054,558 | 144,011,839 |
| Noncontrolling interests | (23,273,499) | (18,140,502) |
| Total stockholders’ equity | 95,781,059 | 125,871,337 |
| Total liabilities and stockholders’ equity | $ 186,816,249 | $ 217,103,012 |
| DocGo Inc. and Subsidiaries UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | ||||
|---|---|---|---|---|
| Three Months EndedJune 30, | Six Months Ended June 30, | |||
| 2026 | 2025 | 2026 | 2025 | |
| Revenues, net | $ 73,424,719 | $ 80,417,622 | $ 148,975,203 | $ 176,450,677 |
| Expenses: | ||||
| Cost of revenues (exclusive of depreciation and amortization, which is shown separately below) | 51,018,120 | 54,998,524 | 102,685,708 | 120,183,584 |
| Operating expenses: | ||||
| General and administrative | 29,742,190 | 31,240,943 | 60,577,258 | 64,143,013 |
| Depreciation and amortization | 2,691,411 | 3,981,008 | 5,338,518 | 7,742,399 |
| Legal and regulatory | 4,025,638 | 4,351,974 | 9,059,768 | 8,562,797 |
| Technology and development | 3,446,289 | 2,957,203 | 7,151,338 | 6,596,647 |
| Sales, advertising and marketing | 423,294 | 368,214 | 795,927 | 699,919 |
| Total expenses | 91,346,942 | 97,897,866 | 185,608,517 | 207,928,359 |
| Loss from operations | (17,922,223) | (17,480,244) | (36,633,314) | (31,477,682) |
| Other (expense) income: | ||||
| Interest expense, net | (97,583) | (443,662) | (197,315) | (869,946) |
| Loss on change in fair value of contingent consideration | — | — | (2,760,000) | — |
| Insurance proceeds | — | — | 4,687,798 | — |
| Loss on equity method investment | — | (38,817) | — | (79,515) |
| Loss on remeasurement of operating and finance leases | — | (6,607) | — | (47,444) |
| Loss on disposal of fixed assets | (39,574) | (48,354) | (102,067) | (33,215) |
| Other income (expense) | 123,211 | 101,046 | 388,175 | (211,823) |
| Total other (expense) income | (13,946) | (436,394) | 2,016,591 | (1,241,943) |
| Net loss before income tax (provision) benefit | (17,936,169) | (17,916,638) | (34,616,723) | (32,719,625) |
| (Provision for) benefit from income taxes | (56,129) | 4,626,745 | (75,412) | 8,350,432 |
| Net loss | (17,992,298) | (13,289,893) | (34,692,135) | (24,369,193) |
| Net loss attributable to noncontrolling interests | (2,172,021) | (2,134,647) | (4,108,727) | (3,808,632) |
| Net loss attributable to stockholders of DocGo Inc. and Subsidiaries | (15,820,277) | (11,155,246) | (30,583,408) | (20,560,561) |
| Other comprehensive (loss) income | ||||
| Unrealized loss on investments, net of tax | (54,965) | 76,733 | (126,869) | 76,733 |
| Foreign currency translation adjustment | (23,730) | 927,462 | (91,246) | 1,423,000 |
| Total comprehensive loss | $ (15,898,972) | $ (10,151,051) | $ (30,801,523) | $ (19,060,828) |
| Net loss per share attributable to DocGo Inc. and Subsidiaries - Basic | $ (0.16) | $ (0.11) | $ (0.31) | $ (0.21) |
| Weighted-average shares outstanding - Basic | 98,802,810 | 98,931,293 | 98,774,609 | 100,255,877 |
| Net loss per share attributable to DocGo Inc. and Subsidiaries - Diluted | $ (0.16) | $ (0.11) | $ (0.31) | $ (0.21) |
| Weighted-average shares outstanding - Diluted | 98,802,810 | 98,931,293 | 98,774,609 | 100,255,877 |
| DocGo Inc. and Subsidiaries UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||
|---|---|---|---|---|
| Three Months Ended June 30, | Six Months Ended June 30, | |||
| 2026 | 2025 | 2026 | 2025 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||
| Net loss | $ (17,992,298) | $ (13,289,893) | $ (34,692,135) | $ (24,369,193) |
| Adjustments to reconcile net loss to net cash (used in) provided by operating activities: | ||||
| Depreciation of property and equipment | 1,238,431 | 1,211,771 | 2,504,944 | 2,432,577 |
| Amortization of intangible assets | 62,041 | 1,452,299 | 83,079 | 2,751,441 |
| Amortization of finance lease right-of-use assets | 1,390,939 | 1,316,938 | 2,750,495 | 2,558,381 |
| Loss on disposal of fixed assets | 39,574 | 48,354 | 102,067 | 33,215 |
| Deferred income tax expense | 266,738 | (4,878,785) | 12,963 | (8,806,213) |
| Accretion of discount related to restricted investments | (86,378) | (145,403) | (164,382) | (145,403) |
| Loss on equity method investments | — | 38,817 | — | 79,515 |
| Bad debt expense | 1,106,983 | 1,244,018 | 2,839,894 | 2,492,009 |
| Stock-based compensation | 2,655,526 | 4,826,133 | 5,880,310 | 9,656,445 |
| Loss on remeasurement of operating and finance leases | — | 6,607 | — | 47,444 |
| Loss on change in fair value of contingent consideration | — | — | 2,760,000 | — |
| Changes in operating assets and liabilities: | ||||
| Accounts receivable | 6,640,909 | 54,756,572 | 3,837,143 | 86,194,306 |
| Prepaid expenses and other current assets | 179,571 | (4,886,326) | 141,899 | (5,273,060) |
| Other assets | (143,358) | 432,422 | (126,984) | 970,612 |
| Accounts payable | 117,261 | (9,938,620) | 2,817,762 | (18,246,793) |
| Accrued liabilities | (4,460,761) | 1,697,323 | (2,522,047) | (7,451,661) |
| Operating lease liabilities and right-of-use assets | (256,730) | 151,262 | (124,367) | 336,596 |
| Net cash (used in) provided by operating activities | (9,241,552) | 34,043,489 | (13,899,359) | 43,260,218 |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||
| Purchase of property and equipment | (320,832) | (1,141,257) | (751,142) | (2,170,883) |
| Purchase of intangibles | (828,161) | (865,462) | (1,493,333) | (1,578,173) |
| Acquisition of a business, net of cash acquired | — | — | — | (3,646,318) |
| Purchase of restricted investments | (5,745,440) | (22,221,437) | (7,476,506) | (22,221,437) |
| Proceeds from sale and maturity of restricted investments | 2,995,663 | 2,329,246 | 7,459,428 | 2,329,246 |
| Proceeds from disposal of property and equipment | 22,660 | 82,988 | 44,563 | 177,329 |
| Net cash used in investing activities | (3,876,110) | (21,815,922) | (2,216,990) | (27,110,236) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||
| Repayments of notes payable | (13,659) | (3,198) | (28,210) | (6,258) |
| Due to seller | (75,835) | (750,919) | (75,835) | (750,919) |
| Earnout payments on contingent liabilities | — | — | — | (265,538) |
| Distributions paid to noncontrolling interest | — | — | (1,024,270) | — |
| Payments for taxes related to shares withheld for employee taxes | (13,865) | (139,575) | (36,068) | (1,340,552) |
|---|---|---|---|---|
| Common stock repurchased | — | (5,076,952) | — | (10,828,906) |
| Payments on obligations under finance lease | (1,559,799) | (1,411,786) | (2,963,454) | (2,708,673) |
| Net cash used in financing activities | (1,663,158) | (7,382,430) | (4,127,837) | (15,900,846) |
| Effect of exchange rate changes on cash and cash equivalents | 136,599 | 650,391 | (69,477) | 968,129 |
| Net (decrease) increase in cash, cash equivalents, restricted cash and restricted cash equivalents | (14,644,221) | 5,495,528 | (20,313,663) | 1,217,265 |
| Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period | 46,815,336 | 103,059,044 | 52,484,778 | 107,337,307 |
| Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period | $ 32,171,115 | $ 108,554,572 | $ 32,171,115 | $ 108,554,572 |
| Three Months Ended June 30, | Six Months Ended June 30, | |||
| 2026 | 2025 | 2026 | 2025 | |
| Supplemental disclosure of cash and non-cash transactions: | ||||
| Cash paid for interest | $ 49,081 | $ 444,062 | $ 96,112 | $ 1,005,769 |
| Cash paid for interest on finance lease liabilities | $ 249,258 | $ 250,694 | $ 497,826 | $ 470,749 |
| Cash paid for income taxes | $ 154,400 | $ 4,187,558 | $ 170,191 | $ 6,094,270 |
| Right-of-use assets obtained in exchange for lease liabilities | $ 945,640 | $ 1,732,734 | $ 3,059,931 | $ 7,698,829 |
| Supplemental non-cash investing and financing activities: | ||||
| Property and equipment in accounts payable | $ 37,296 | $ (425,613) | $ 92,331 | $ 13,125 |
| Reconciliation of cash and restricted cash | ||||
| Cash | $ 25,233,369 | $ 104,164,128 | $ 25,233,369 | $ 104,164,128 |
| Restricted cash | 6,937,746 | 4,390,444 | 6,937,746 | 4,390,444 |
| Total cash and restricted cash shown in statement of cash flows | $ 32,171,115 | $ 108,554,572 | $ 32,171,115 | $ 108,554,572 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.